Hepatitis Therapeutics Market Trends That Will Shape the Next Decade: Insights from Advancing Hepatitis Therapeutics: Recent Innovations And Fda Approval Of Vemlidy By Gilead Sciences, Inc

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

How Large Will the Hepatitis Therapeutics Market Size By 2025?
The market size for hepatitis therapeutics has seen consistent growth over the years. There is an anticipated rise from $18.66 billion in 2024 to $19.27 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 3.2%. Factors like vaccine creation, antiviral drugs, initiatives in public health, funding for research, and budding therapies are the primary reasons for this historical growth.

How Big Is the Hepatitis Therapeutics Market Size Expected to Grow by 2029?
In the coming years, the market size for hepatitis therapeutics is predicted to experience stable expansion, with estimates pegging its value at $22.75 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.2%. This growth over the forecast period can be attributed to various factors such as ongoing research and development, worldwide health initiatives, changes in patient care, government policies, and increasing awareness of the disease. The forecast period also expects significant trends like patient advocacy and support, continuous observation and follow-up interventions, healthcare fairness, telehealth and remote care, with a particular emphasis on the eradication of hepatitis C.

View the full report here:
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Which Key Market Drivers Powering Hepatitis Therapeutics Market Expansion and Growth?
The global increase in hepatitis infections is projected to drive the growth of hepatitis therapeutics market. This surge in hepatitis cases is attributed to factors such as limited access to healthcare services and vaccines, growing instances of intravenous drug consumption, unsafe practices of blood transfusion, and substandard sanitation and hygiene conditions in certain areas of the world. For example, the World Health Organization (WHO), a US-based public health agency of the United Nations, reported in April 2022 that at least 169 cases of acute hepatitis of unidentified origin were recorded in 11 countries, and a staggering 350 million people globally suffer from viral hepatitis B or C. However, the majority still struggle to access appropriate testing and treatment facilities. Hence, these factors are contributing to the expansion of the hepatitis therapeutics market due to the escalation in hepatitis infections.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9956&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Hepatitis Therapeutics Market?
Product innovation is becoming a significant trend in the hepatitis therapeutics market, with major companies creating new products to maintain their market presence. An example of this is when Gilead Sciences, Inc., a biopharmaceutical company based in the US, received FDA approval in November 2022 for a drug named Vemlidy (tenofovir alafenamide), for the treatment of pediatric patients with chronic hepatitis B virus infection. Vemlidy is a prodrug of tenofovir, which in 2016 got FDA approval as a daily treatment for individuals with chronic hepatitis B virus (HBV) infection and compensated liver disease. The American Liver Foundation has recommended it as a preferred or primary treatment for people with chronic HBV and compensated liver disease.

What Are the Emerging Segments in the Hepatitis Therapeutics Market?
The hepatitis therapeutics market covered in this report is segmented -

1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Drug Class: Oral Antivirals, Immune Modulators
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Subsegments:
1) By Hepatitis A: Vaccines, Post-Exposure Prophylaxis (PEP)
2) By Hepatitis B: Antiviral Medications, Immune Modulators, Vaccines
3) By Hepatitis C: Direct-Acting Antivirals (DAAs), Ribavirin, Interferon-Based Therapies
4) By Other Disease Types: Hepatitis D, Hepatitis E, Other Viral Hepatitis Infections

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9956&type=smp

Who Are the Global Leaders in the Hepatitis Therapeutics Market?
Major companies operating in the hepatitis therapeutics market include Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Biocon Biopharmaceuticals Pvt. Ltd.

Which are the Top Profitable Regional Markets for the Hepatitis Therapeutics Industry?
North America was the largest region in the hepatitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9956

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.